Pharma BD Deal Intelligence
A co-development licensing deal, not an acquisition—AbbVie paid MedinCell just $35M upfront for rights to up to six long-acting injectable programs built on its BEPO platform, with up to $1.9B in milestones tied to future development. Slow-burn: one candidate has advanced through preclinical work with first-in-human trials targeted for 2026.
MedinCell enters strategic co-development agreement with AbbVie for next-generation long-acting injectable therapies worth up to $1.9B.
MedinCell and AbbVie enter injectable therapy deal with $35M upfront and up to $1.9B in milestones.
Revenues from the 1st program in development under the AbbVie collaboration accounted for EUR 4.9 million; regulatory package to initiate first human trials…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
In April 2024 AbbVie entered a strategic co-development and licensing agreement with MedinCell (Euronext: MEDCL) to develop up to six next-generation long-acting injectable (LAI) therapies built on MedinCell's BEPO technology across multiple therapeutic areas. MedinCell received a $35M upfront payment and is eligible for up to $1.9B in development and commercial milestones ($315M per program across up to six programs) plus mid-single to low-double-digit royalties; MedinCell runs formulation and preclinical/CMC work while AbbVie funds and conducts clinical development, regulatory approval, manufacturing and commercialization. Since signing, the first LAI program candidate has been selected and advanced through preclinical and CMC activities; MedinCell expects the regulatory package to initiate first-in-human trials to be ready in 2026, enabling AbbVie to take the lead candidate into the clinic. The collaboration generated EUR 4.9M of co-development revenue for MedinCell in the first half of fiscal 2025-26 (six months ended September 30, 2025). No milestone payment beyond the $35M upfront has been publicly disclosed.
$50.0B Global LAI Market (2028E)
AbbVie/MedinCell co-developing up to 6 LAI therapies using BEPO polymer technology. First candidate selected, formulation underway. BEPO validated with Uzedy (risperidone LAI, approved 2023).
MedinCell handles formulation/preclinical; AbbVie handles clinical/regulatory/commercial. $35M upfront + $1.9B milestones across 6 programs.
AbbVie partnered with MedinCell on up to six long-acting injectable formulations.
MedinCell selected the first program candidate under the AbbVie LAI collaboration and started preclinical and CMC activities to advance it toward clinical development.
MedinCell H1 FY2025-26 results (six months ended Sept 30, 2025) reported EUR 4.9M of co-development revenue from the first AbbVie LAI program; the regulatory package to initiate first-in-human trials is expected ready in 2026.
Multi-program LAI formulation collaboration. Preclinical stage across multiple therapeutic areas.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / MedinCell S.A. (this deal) | 2024 | $1.9B | 61 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals